Abstract
August 2015 e11 −3.5 to 11.7; 26.8; CI, 17.6 to 36.8, respectively), a subjective visual analogue scale for alertness (−1.3; CI, −3.7 to 1.2; −2.5; CI, −4.8 to −0.2; −5.3; CI, −7.7 to −2.9, respectively) and saccadic peak velocity (−14.3; CI, 33.5 to 4.8; −10.9; CI, −29.0 to 7.1; −25.4 (CI, −44.2 to −6.6, respectively), a marker for sedation. Mecamylamine was well tolerated and had linear pharmacokinetics over the dose range tested. Conclusion: The pharmacological challenge model with mecamylamine 20 mg in healthy subjects leads to a reproducible pattern of cognitive disturbance that is nicotinic receptor specific. This model may be more suitable for proof of pharmacology and dose finding studies of nicotinic receptor agonists than the frequently used scopolamine model.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
